The Rise of Prostate Cancer Genetic Testing
Use of PCa genetic testing to stratify risk and guide screening and management continues to gain momentum.
Use of PCa genetic testing to stratify risk and guide screening and management continues to gain momentum.
The new report adds to growing evidence of COVID-19’s adverse effects on the kidneys.
Among patients with renal cell carcinoma, those on hemodialysis have a 5 times higher risk of dying from the cancer than those not on dialysis, a study found.
In a study of men on active surveillance for low-risk prostate cancer, multiparametric magnetic resonance imaging by itself missed about one-fifth of men who had pathologic upgrading on subsequent biopsies.
A new analysis looking at the effect of PSA screening on prostate cancer mortality over a 25-year period found a more favorable balance of benefits and harms than the 16-year estimates from the European Randomized Study of Screening for Prostate Cancer.
Patients with LN who received belimumab in addition to standard therapy experienced a significant 49% decreased risk of renal-related events or death compared with those who received placebo plus standard therapy, a phase 3 study found.